{"protocolSection":{"identificationModule":{"nctId":"NCT00660764","orgStudyIdInfo":{"id":"25V07"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)","officialTitle":"Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)","acronym":"HEROS"},"statusModule":{"statusVerifiedDate":"2009-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-05"},"completionDateStruct":{"date":"2005-04","type":"ACTUAL"},"studyFirstSubmitDate":"2008-04-15","studyFirstSubmitQcDate":"2008-04-16","studyFirstPostDateStruct":{"date":"2008-04-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-03-13","lastUpdatePostDateStruct":{"date":"2009-03-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Elisabeth Björk - Medical Science Director","oldOrganization":"AstraZeneca"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied."},"conditionsModule":{"conditions":["Hypercholesterolemia","Coronary Heart Disease","Peripheral Vascular Disease","Cerebrovascular Accident","Diabetes"],"keywords":["cholesterol","coronary heart disease","rosuvastatin","LDL-C goal","hypercholesterolemia","secondary prevention","primary prevention","CVA"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"}},"armsInterventionsModule":{"armGroups":[{"label":"1","description":"Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca","interventionNames":["Drug: Rosuvastatin"]}],"interventions":[{"type":"DRUG","name":"Rosuvastatin","description":"Oral","armGroupLabels":["1"],"otherNames":["Crestor"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.","timeFrame":"2 year"}],"secondaryOutcomes":[{"measure":"Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l.\n* According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention.\n* The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation.\n* Patient approved to place anonymous results at the disposal of AstraZeneca\n\nExclusion Criteria:\n\n* Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"patients of practices of General Practioners","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ingrid van Geel","affiliation":"CV","role":"STUDY_CHAIR"},{"name":"Ingeborg Vosjan","affiliation":"CV","role":"STUDY_CHAIR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000003327","term":"Coronary Disease"},{"id":"D000003324","term":"Coronary Artery Disease"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000016491","term":"Peripheral Vascular Diseases"},{"id":"D000058729","term":"Peripheral Arterial Disease"},{"id":"D000006937","term":"Hypercholesterolemia"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000006949","term":"Hyperlipidemias"},{"id":"D000050171","term":"Dyslipidemias"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000050197","term":"Atherosclerosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M6805","name":"Diabetes Mellitus","relevance":"LOW"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Coronary Heart Disease","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","asFound":"Coronary Heart Disease","relevance":"HIGH"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Coronary Heart Disease","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","asFound":"Heart Disease","relevance":"HIGH"},{"id":"M28903","name":"Peripheral Arterial Disease","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M18584","name":"Peripheral Vascular Diseases","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","asFound":"Vascular Disease","relevance":"HIGH"},{"id":"M9678","name":"Hypercholesterolemia","asFound":"Hypercholesterolemia","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M9690","name":"Hyperlipidemias","relevance":"LOW"},{"id":"M9692","name":"Hyperlipoproteinemias","relevance":"LOW"},{"id":"M25871","name":"Dyslipidemias","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M26719","name":"Lipid Metabolism Disorders","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068718","term":"Rosuvastatin Calcium"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M298","name":"Rosuvastatin Calcium","asFound":"Movement","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"}]}},"hasResults":false}